UP­DAT­ED: In sur­prise switch, Bris­tol-My­ers is sell­ing off block­buster Ote­zla, promis­ing to com­plete Cel­gene ac­qui­si­tion — just lat­er

19 hours ago
Deals

Why would the FDA ap­prove an­oth­er con­tro­ver­sial drug to spur a woman’s li­bido with these da­ta? And why no ex­pert pan­el re­view?

2 days ago
Bioregnum
Pharma

Which top 10 big phar­mas have the most to gain — or lose — over the next 5 years?

3 days ago
Pharma

HIV, pneu­mo­coc­cal — and what? Mer­ck­'s un­ex­pect­ed pipeline high­light ex­cites a lit­tle biotech

3 days ago
R&D

Who’s next in line to suc­ceed Ken Fra­zier as CEO of the Keytru­da-blessed Mer­ck?

4 days ago
People

Sanofi's John Reed con­tin­ues to re­or­ga­nize R&D, cut­ting 466 jobs while boost­ing can­cer, gene ther­a­py re­search

5 days ago
R&D

A new num­ber 1 drug? Keytru­da tapped to top the 10 biggest block­busters on the world stage by 2024

5 days ago
Pharma

'It's a growth play': Catal­ent ac­quires Bris­tol-My­er­s' Eu­ro­pean launch pad, ex­pand­ing glob­al CD­MO ops

5 days ago
Deals
Outsourcing

Af­ter watch­ing its share price soar on a Bloomberg re­port and heat­ed ru­mors, Bio­haven stock takes a bil­lion-dol­lar bath

6 days ago
Bioregnum

The top 10 block­buster drugs in the late-stage pipeline — Eval­u­ate adds 6 new ther­a­pies to heavy-hit­ter list

6 days ago
R&D

As Bris­tol-My­ers/Cel­gene tie up loose ends, BeiGene pock­ets $150M from PD-1 breakup

Last week
China
Deals

Pfiz­er CEO Al­bert Bourla is back in the M&A game, but why is he pay­ing $11.4B for Ar­ray?

Last week
Deals

Glob­al Blood Ther­a­peu­tics poised to sub­mit ap­pli­ca­tion for ac­cel­er­at­ed ap­proval, with new piv­otal da­ta on its sick­le cell dis­ease drug

Last week
R&D

Gene ther­a­pies seize the top of the list of the most ex­pen­sive drugs on the plan­et — and that trend has just be­gun

Last week
Cell/Gene Tx
Pharma

As an­oth­er an­tibi­otics biotech sinks in­to a cri­sis, warn­ings of a sec­tor ‘col­lapse’

Last week
R&D

Bain’s biotech team has cre­at­ed a $1B-plus fund — with an eye to more Big Phar­ma spin­outs

Last week
Venture

Search­ing for the next block­buster to fol­low Darza­lex, J&J finds a $150M an­ti-CD38 drug from part­ner Gen­mab

Last week
R&D

Mer­ck makes a $773M bet on TGFβ, ac­quir­ing a three-year-old biotech

2 weeks ago
Deals

As in­vestor con­fi­dence crum­bles fol­low­ing fund sus­pen­sion, Neil Wood­ford faces back­lash on fees

3 weeks ago
Pharma

R&D leader Ver­tex ex­e­cutes a $420M cash gam­bit to dom­i­nate gene edit­ing field for Duchenne MD

3 weeks ago
Cell/Gene Tx
Deals

Cel­gene can breathe a sigh of re­lief as FDA ac­cepts once-spurned ozan­i­mod ap­pli­ca­tion — set­ting a tar­get date on a block­buster de­ci­sion

3 weeks ago
Pharma

Third Rock rais­es a record $770M to back its own brand of biotech star­tups — while 1 key part­ner ex­its

3 weeks ago
Startups

In­flaRx shares shat­tered as lead drug flops bad­ly in a PhI­Ib tri­al while Chemo­Cen­tryx is caught in the smash up

3 weeks ago
Pharma
R&D

The Wash­ing­ton Post points the fin­ger at Pfiz­er for stay­ing mum about an Alzheimer’s study. But there’s more to the sto­ry than that

3 weeks ago
Bioregnum
Pharma
1234 Next page Last page